As the second most prevalent rheumatic autoimmune disease, Sj枚gren鈥檚 disease represents a significant area of unmet need. Learn about our new data presented at #ACR26 highlighting 2-year treatment results in this disease area. 馃敆 novartis.social/6019ah8yB
0:15